2023 World Conference on Lung Cancer (Posters)-EP12.01. Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review

EP12.01. Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review - PDF(Slides)

Back to course

Pdf Summary

This document provides a summary of a systematic literature review on the treatment patterns and outcomes of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The review included 394 unique studies, including randomized control trials (RCTs) and observational studies, conducted between January 2017 and September 2022.<br /><br />The findings indicate that while EGFR tyrosine kinase inhibitors (TKIs) have transformed the treatment of patients with EGFR-mutated advanced or metastatic NSCLC in earlier lines of therapy, patient outcomes are suboptimal in later lines of therapy. In the second-line setting, platinum-based chemotherapy (PBC) and immuno-oncology (IO) based regimens have only demonstrated a median progression-free survival (mPFS) benefit of 5 months. In the third-line setting, salvage regimens have shown even less benefit, with mPFS below 3 months.<br /><br />The study also found that EGFR TKIs generally have fewer serious adverse events than standard chemotherapy. However, interstitial lung disease (ILD) was reported as an adverse event in some studies, although the occurrence was low.<br /><br />The racial breakdown of patients in the international RCTs varied, with the median percentage of Asian patients being 61.9% and the median percentage of White patients being 32.7%. There were also small percentages of patients from other racial groups.<br /><br />Overall, the findings highlight the need for new effective and tolerable treatment options for patients with NSCLC progressing on EGFR TKIs, especially in later lines of therapy. The study acknowledges the limitations of the systematic literature review, including the inability to account for prognostic factors and the duration of exposure in comparing safety outcomes.<br /><br />In conclusion, this review provides valuable insights into the current treatment patterns and outcomes in patients with EGFR-mutated NSCLC, emphasizing the need for further research and development of novel therapies for this patient population.

Asset Subtitle

Shirish Gadgeel

Meta Tag

Speaker Shirish Gadgeel

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

systematic literature review

treatment patterns

metastatic non-small cell lung cancer

EGFR mutations

tyrosine kinase inhibitors

chemotherapy

progression-free survival

adverse events

racial breakdown

novel therapies